Liquid Biopsy Market by Product & Service (Kits & Reagents, Platforms & Instruments, and Services), Circulating Biomarker (Circulating Tumor Cells, Extracellular Vesicles, Circulating Tumor DNA [ctDNA], and Other Biomarkers), Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer, and Other Cancers), and End User (Hospitals & Laboratories and Government & Academic Research Centers): Global Opportunity Analysis and Industry Forecast, 2021–2028
- ALL4621682
- 235 Pages
- May 2021
- Medical Devices
Liquid biopsy is a simple and precise alternative to surgical biopsies, which allows physicians & surgeons to detect & treat cancer at an early stage and acquire tumor information through blood samples. Liquid biopsy also enables the detection of cancer recurrence at earlier than traditional diagnosis methods. Early diagnosis enabled by liquid biopsy tests help healthcare professionals to improve various cancer treatments.
Currently, there are several liquid biopsies in development for oncology. These technological applications and services are being developed for various purposes from research to screening & early detection, assessing biomarker, and providing insights on prognosis & treatment selection. Moreover, some of these tests focus on specific cancer and others are being developed as screening tool for multiple solid tumor cancers.
Rise in incidences and prevalence of various cancer types, advantages of liquid biopsy technology, surge in demand of non-invasive procedures, and favorable government initiatives supplement the market growth. However, lack of awareness about cancer and its risk factors, along with limited access to advanced cancer diagnostics technologies in developing regions are expected to hinder the market growth. Furthermore, advantages of liquid biopsy over traditional invasive diagnostics methods is expected to present lucrative growth opportunities for the market.
The liquid biopsy market is categorized on the basis of product & service, cancer type, circulating biomarker, end user, and region. By product & service, it is divided into kits & reagents, platforms & instruments, and services. By cancer type, it is classified into lung cancer, breast cancer, colorectal cancer, prostate cancer, liver cancer, and other cancers. By circulating biomarker, it is categorized into circulating tumor cell, extracellular vesicle, circulating tumor DNA [ctDNA], and other biomarkers. By end user, it is classified into hospital & laboratory and government & research centers. By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Prominent players operating in the global liquid biopsy market include Bio-Rad Laboratories, Inc, Biocept Inc., Guardant Health Inc., Illumina, Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson, Laboratory Corporation of America Holdings, MDxHealth SA, QIAGEN N.V., and Thermo Fisher Scientific Inc. Product development is the key strategy adopted by the market players to establish their foothold in the market.
KEY BENEFITS FOR STAKEHOLDERS
• The study provides an in-depth analysis of the global liquid biopsy market with current trends and future estimations from 2021 to 2028 to elucidate the imminent investment pockets.
• Comprehensive analysis of factors that drive and restrict the market growth is provided.
• Identification of factors instrumental in changing the market scenario, rise in opportunities, and identification of key companies that can influence this market on a global & regional scale are provided.
• Key players are profiled, and their strategies are analyzed thoroughly to understand the competitive outlook of the market.
Key Market Segments
BY PRODUCT & SERVICE
• Kits & Reagents
• Platforms & Instruments
• Services
BY CIRCULATING BIOMARKER
• Circulating Tumor Cells
• Extracellular Vesicles
• Circulating Tumor DNA [ctDNA]
• Other Biomarkers
BY CANCER TYPE
• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Prostate Cancer
• Liver Cancer
• Other Cancers
BY REGION
o North America
U.S.
Canada
Mexico
o Europe
UK
Germany
France
Italy
Spain
Rest of Europe
o Asia-Pacific
China
Japan
India
Australia
South Korea
Taiwan
Rest of Asia-Pacific
o LAMEA
• Brazil
• Turkey
• Saudi Arabia
• South Africa
• Rest of LAMEA
List of key players profiled in the report
• Bio-Rad Laboratories, Inc
• Biocept Inc.
• Guardant Health Inc.
• Illumina, Inc.
• F. Hoffmann-La Roche Ltd.
• Johnson & Johnson
• Laboratory Corporation of America Holdings
• MDxHealth SA
• QIAGEN N.V
• Thermo Fisher Scientific Inc.
List of the other key players (not included in the report) includes ArcherDX, Inc., CellMax Life, Epigenomics AG, GRAIL Inc., Freenome Holdings Inc, and others.
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.2.3.Bargaining power of buyers
3.2.4.Bargaining power of suppliers
3.2.5.Thereat of new entrants
3.2.6.Threat of substitutes
3.2.7.Intensity of competitive rivalry
3.3.Top player positioning, 2020
3.1.Regulation
3.2.Market dynamics
3.2.1.Drivers
3.2.1.1.Rise in incidences and prevalence of various cancer types
3.2.1.2.Increase in demand for safe and non-invasive procedures
3.2.1.3.Advantages of liquid biopsy launches and technology
3.2.2.Restraints
3.2.2.1.Lack of awareness in developing and underdeveloped regions
3.2.3.Opportunities
3.2.3.1.Use of liquid biopsy for treatment of rare cancer
3.2.3.2.Untapped potential of emerging markets
3.3.Impact Analysis
3.4.Impact Analysis of the Covid-19 on Liquid Biopsy Market
CHAPTER 4:LIQUID BIOPSY MARKET, BY PRODUCT & SERVICES
4.1.Overview
4.1.1.Market size and forecast
4.2.Kits & Reagents
4.2.1.Key market trends and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market share analysis, by country
4.3.Platforms & Instruments
4.3.1.Key market trends and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market share analysis, by country
4.4.Services
4.4.1.Key market trends and opportunities
4.4.2.Market size and forecast
4.4.3.Market share analysis, by country
CHAPTER 5:LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER
5.1.Overview
5.1.1.Market size and forecast
5.2.Circulating Tumor Cell
5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country
5.3.Circulating Tumor DNA
5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country
5.4.Extracellular Vesicles
5.4.1.Market size and forecast, by region
5.4.2.Market analysis, by country
5.5.Other Biomarkers
5.5.1.Market size and forecast, by region
5.5.2.Market analysis, by country
CHAPTER 6:LIQUID BIOPSY MARKET, BY CANCER TYPE
6.1.Overview
6.1.1.Market size and forecast
6.2.Lung Cancer
6.2.1.Market size and forecast, by region
6.2.2.Market analysis, by country
6.3.Breast Cancer
6.3.1.Market size and forecast, by region
6.3.2.Market analysis, by country
6.5.Colorectal Cancer
6.5.1.Market size and forecast, by region
6.5.2.Market analysis, by country
6.6.Prostate cancer
6.6.1.Market size and forecast, by region
6.6.2.Market analysis, by country
6.7.Liver cancer
6.7.1.Market size and forecast, by region
6.7.2.Market analysis, by country
6.8.Other Cancers
6.8.1.Market size and forecast, by region
6.8.2.Market analysis, by country
CHAPTER 7:LIQUID BIOPSY MARKET, BY END USER
7.1.Overview
7.1.1.Market size and forecast
7.2.Hospital and Laboratory
7.2.1.Market size and forecast, by region
7.2.2.Market analysis, by country
7.3.Government and Academic Research Centers
7.3.1.Market size and forecast, by region
7.3.2.Market analysis, by country
CHAPTER 8:LIQUID BIOPSY MARKET, BY REGION
8.1.Overview
8.1.1.Market size and forecast
8.2.North America
8.2.1.Key market trends, growth factors, and opportunities
8.2.2.North America Liquid Biopsy Market, by Product & Service
8.2.3.North America Liquid Biopsy Market, by Circulating Biomarker
8.2.4.North America Liquid Biopsy Market, by Cancer Type
8.2.5.North America Liquid Biopsy Market, by End User
8.2.6.Market size and forecast, by country
8.2.7.U.S.
8.2.7.1.U.S. Liquid biopsy market, by Product & Service
8.2.7.2.U.S. Liquid biopsy market, by Circulating Biomarker
8.2.7.3.U.S. Liquid biopsy market, by Cancer Type
8.2.7.4.U.S. Liquid biopsy market, by End User
8.2.8.Canada
8.2.8.1.Canada Liquid biopsy market, by Product & Service
8.2.8.2.Canada Liquid biopsy market, by Circulating Biomarker
8.2.8.3.Canada Liquid biopsy market, by Cancer Type
8.2.8.4.Canada Liquid biopsy market, by End User
8.2.9.Mexico
8.2.9.1.Mexico Liquid biopsy market, by Product & Service
8.2.9.2.Mexico liquid biopsy market, by Circulating Biomarker
8.2.9.3.Mexico Liquid biopsy market, by Cancer Type
8.2.9.4.Mexico Liquid biopsy market, by End User
8.3.Europe
8.3.1.Key market trends, growth factors, and opportunities
8.3.3.Europe Market size and forecast, by Product & Service
8.3.4.Europe Market size and forecast, by Circulating Biomarker
8.3.5.Europe Market size and forecast, by Cancer Type
8.3.6.Europe Market size and forecast, by End User
8.3.7.Market size and forecast, by country
8.3.8.Germany
8.3.8.1.Germany Liquid biopsy market, by Product & Service
8.3.8.2.Germany Liquid Biopsy Market, by Circulating Biomarker
8.3.8.3.Germany Liquid Biopsy Market, by Cancer Type
8.3.8.4.Germany Liquid Biopsy Market, by End User
8.3.9.France
8.3.9.1.France Liquid biopsy market, by Product & Service
8.3.9.2.France Liquid Biopsy Market, by Circulating Biomarker
8.3.9.3.France Liquid Biopsy Market, by Cancer Type
8.3.9.4.France Liquid Biopsy Market, by End User
8.3.10.UK
8.3.10.1.UK Liquid biopsy market, by Product & Service
8.3.10.2.UK Liquid Biopsy Market, by Circulating Biomarker
8.3.10.3.UK Liquid Biopsy Market, by Cancer Type
8.3.10.4.UK Liquid Biopsy Market, by End User
8.3.11.Italy
8.3.11.1.Italy Liquid biopsy market, by Product & Service
8.3.11.2.Italy Liquid Biopsy Market, by Circulating Biomarker
8.3.11.3.Italy Liquid Biopsy Market, by Cancer Type
8.3.11.4.Italy Liquid Biopsy Market, by End User
8.3.12.Spain
8.3.12.1.Spain Liquid biopsy market, by Product & Service
8.3.12.2.Spain Liquid Biopsy Market, by Circulating Biomarker
8.3.12.3.Spain Liquid Biopsy Market, by Cancer Type
8.3.12.4.Spain Liquid Biopsy Market, by End User
8.3.13.Rest of Europe
8.3.13.1.Rest of Europe Liquid biopsy market, by Product & Service
8.3.13.2.Rest of Europe Liquid Biopsy Market, by Circulating Biomarker
8.3.13.3.Rest of Europe Liquid Biopsy Market, by Cancer Type
8.3.13.4.Rest of Europe Liquid Biopsy Market, by End User
8.4.Asia-Pacific
8.4.1.Key market trends and opportunities
8.4.2.Asia-Pacific Market size and forecast, by Product & Service
8.4.3.Asia-Pacific Market size and forecast, by Circulating Biomarker
8.4.4.Asia-Pacific Market size and forecast, by Cancer Type
8.4.5.Asia-Pacific Market size and forecast, by End User
8.4.6.Market size and forecast, by country
8.4.7.Japan
8.4.7.1.Japan Liquid Biopsy Market, by Product & Service
8.4.7.2.Japan Liquid Biopsy Market, by Circulating Biomarker
8.4.7.3.Japan Liquid Biopsy Market, by Cancer Type
8.4.7.4.Japan Liquid Biopsy Market, by End User
8.4.8.China
8.4.8.1.China Liquid Biopsy Market, by Product & Service
8.4.8.2.China Liquid Biopsy Market, by Circulating Biomarker
8.4.8.3.China Liquid Biopsy Market, by Cancer Type
8.4.8.4.China Liquid Biopsy Market, by End User
8.4.9.Australia
8.4.9.1.Australia Liquid Biopsy Market, by Product & Service
8.4.9.2.Australia Liquid Biopsy Market, by Circulating Biomarker
8.4.9.3.Australia Liquid Biopsy Market, by Cancer Type
8.4.9.4.Australia Liquid Biopsy Market, by End User
8.4.10.India
8.4.10.1.India Liquid Biopsy Market, by Product & Service
8.4.10.2.India Liquid Biopsy Market, by Circulating Biomarker
8.4.10.3.India Liquid Biopsy Market, by Cancer Type
8.4.10.4.India Liquid Biopsy Market, by End User
8.4.11.South Korea
8.4.11.1.South Korea Liquid Biopsy Market, by Product & Service
8.4.11.2.South Korea Liquid Biopsy Market, by Circulating Biomarker
8.4.11.3.South Korea Liquid Biopsy Market, by Cancer Type
8.4.11.4.South Korea Liquid Biopsy Market, by End User
8.4.12.Taiwan
8.4.12.1.Taiwan Liquid Biopsy Market, by Product & Service
8.4.12.2.Taiwan Liquid Biopsy Market, by Circulating Biomarker
8.4.12.3.Taiwan Liquid Biopsy Market, by Cancer Type
8.4.12.4.Taiwan Liquid Biopsy Market, by End User
8.4.13.Rest of Asia-Pacific
8.4.13.1.Rest of Asia-Pacific Liquid Biopsy Market, by Product & Service
8.4.13.2.Rest of Asia-Pacific Liquid Biopsy Market, by Circulating Biomarker
8.4.13.3.Rest of Asia-Pacific Liquid Biopsy Market, by Cancer Type
8.4.13.4.Rest of Asia-Pacific Liquid Biopsy Market, by End User
8.5.LAMEA
8.5.1.Key market trends, growth factors, and opportunities
8.5.3.LAMEA Market size and forecast, by Product & Service
8.5.4.LAMEA Market size and forecast, by Circulating Biomarker
8.5.5.LAMEA Market size and forecast, by Cancer Type
8.5.6.LAMEA Market size and forecast, by End User
8.5.7.Market size and forecast, by country
8.5.8.Brazil
8.5.8.1.Brazil Liquid Biopsy Market, by Product & Service
8.5.8.2.Brazil Liquid Biopsy Market, by Circulating Biomarker
8.5.8.3.Brazil Liquid Biopsy Market, by Cancer Type
8.5.8.4.Brazil Liquid Biopsy Market, by End User
8.5.9.Turkey
8.5.9.1.Turkey Liquid Biopsy Market, by Product & Service
8.5.9.2.Turkey Liquid Biopsy Market, by Circulating Biomarker
8.5.9.3.Turkey Liquid Biopsy Market, by Cancer Type
8.5.9.4.Turkey Liquid Biopsy Market, by End User
8.5.10.Saudi Arabia
8.5.10.1.Saudi Arabia Liquid Biopsy Market, by Product & Service
8.5.10.2.Saudi Arabia Liquid Biopsy Market, by Circulating Biomarker
8.5.10.3.Saudi Arabia Liquid Biopsy Market, by Cancer Type
8.5.10.4.Saudi Arabia Liquid Biopsy Market, by End User
8.5.11.South Africa
8.5.11.1.South Africa Liquid Biopsy Market, by Product & Service
8.5.11.2.South Africa Liquid Biopsy Market, by Circulating Biomarker
8.5.11.3.South Africa Liquid Biopsy Market, by Cancer Type
8.5.11.4.South Africa Liquid Biopsy Market, by End User
8.5.12.Rest of LAMEA
8.5.12.1.Rest of LAMEA Liquid Biopsy Market, by Product & Service
8.5.12.2.Rest of LAMEA Liquid Biopsy Market, by Circulating Biomarker
8.5.12.3.Rest of LAMEA Liquid Biopsy Market, by Cancer Type
8.5.12.4.Rest of LAMEA Liquid Biopsy Market, by End User
CHAPTER 9:COMPANY PROFILES
9.1.BIO-RAD LABORATORIES, INC.
9.1.1.1.Company overview
9.1.1.2.Company snapshot
9.1.1.3.Operating business segments
9.1.1.4.Product portfolio
9.1.1.5.Business performance
9.1.1.6.Key strategic moves and developments
9.2.BIOCEPT, INC.
9.2.1.1.Company overview
9.2.1.2.Company snapshot
9.2.1.3.Operating business segments
9.2.1.4.Product portfolio
9.2.1.5.Business performance
9.2.1.6.Key strategic moves and developments
9.3.GUARDANT HEALTH INC.
9.3.1.1.Company overview
9.3.1.2.Company snapshot
9.3.1.3.Operating business segments
9.3.1.4.Product portfolio
9.3.1.5.Business performance
9.3.1.6.Key strategic moves and developments
9.4.ILLUMINA, INC.
9.4.1.1.Company overview
9.4.1.2.Company snapshot
9.4.1.3.Operating business segments
9.4.1.4.Product portfolio
9.4.1.5.Business performance
9.4.1.6.Key strategic moves and developments
9.5.F. HOFFMANN-LA ROCHE LTD. (FOUNDATION MEDICINE, INC.)
9.5.1.1.Company overview
9.5.1.2.Company snapshot
9.5.1.3.Operating business segments
9.5.1.4.Product portfolio
9.5.1.5.Business performance
9.5.1.6.Key strategic moves and developments
9.6.JOHNSON & JOHNSON
9.6.1.1.Company overview
9.6.1.2.Company snapshot
9.6.1.3.Operating business segments
9.6.1.4.Product portfolio
9.6.1.5.Business performance
9.7.LABORATORY CORPORATION OF AMERICA HOLDINGS
9.7.1.1.Company overview
9.7.1.2.Company snapshot
9.7.1.3.Operating business segments
9.7.1.4.Product portfolio
9.7.1.5.Business performance
9.7.1.6.Key strategic moves and developments
9.8.MDXHEALTH SA
9.8.1.1.Company overview
9.8.1.2.Company snapshot
9.8.1.3.Operating business segments
9.8.1.4.Product portfolio
9.8.1.5.Business performance
9.8.1.6.Key strategic moves and developments
9.9.QIAGEN N.V.
9.9.1.1.Company overview
9.9.1.2.Company snapshot
9.9.1.3.Operating business segments
9.9.1.4.Product portfolio
9.9.1.5.Business performance
9.9.1.6.Key strategic moves and developments
9.10.THERMO FISHER SCIENTIFIC
9.10.1.1.Company overview
9.10.1.2.Company snapshot
9.10.1.3.Operating business segments
9.10.1.4.Product portfolio
9.10.1.5.Business performance
9.10.1.6.Key strategic moves and developments
TABLE 01.GLOBAL LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020-2028 ($MILLION)
TABLE 02.LIQUID BIOPSY MARKET FOR KITS & REAGENTS, BY REGION, 2020-2028 ($MILLION)
TABLE 03.LIQUID BIOPSY MARKET FOR PLATFORMS & INSTRUMENTS, BY REGION, 2020-2028 ($MILLION)
TABLE 04.LIQUID BIOPSY MARKET FOR SERVICES, BY REGION, 2020-2028 ($MILLION)
TABLE 05.LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 06.LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR CELL, BY REGION, 2020–2028 ($MILLION)
TABLE 07.LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR DNA, BY REGION, 2020–2028 ($MILLION)
TABLE 08.LIQUID BIOPSY MARKET FOR EXTRACELLULAR VESICLES, BY REGION, 2020–2028 ($MILLION)
TABLE 09.LIQUID BIOPSY MARKET FOR OTHERS, FOR OTHER BIOMARKERS, BY REGION, 2020–2028 ($MILLION)
TABLE 10.LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 11.LIQUID BIOPSY MARKET FOR LUNG CANCER, BY REGION, 2020–2028 ($MILLION)
TABLE 12.LIQUID BIOPSY MARKET FOR BREAST CANCER, BY REGION, 2020–2028 ($MILLION)
TABLE 13.LIQUID BIOPSY MARKET FOR COLORECTAL CANCER, BY REGION, 2020–2028 ($MILLION)
TABLE 14.LIQUID BIOPSY MARKET FOR PROSTATE CANCER, BY REGION, 2020–2028 ($MILLION)
TABLE 15.LIQUID BIOPSY MARKET FOR LIVER CANCER, BY REGION, 2020–2028 ($MILLION)
TABLE 16.LIQUID BIOPSY MARKET FOR OTHER CANCER, BY REGION, 2020–2028 ($MILLION)
TABLE 17.LIQUID BIOPSY MARKET, BY END USER, 2020–2028 ($MILLION)
TABLE 18.LIQUID BIOPSY MARKET FOR HOSPITAL AND LABORATORY, BY REGION, 2020–2028 ($MILLION)
TABLE 19.LIQUID BIOPSY MARKET FOR GOVERNMENT AND ACADEMIC RESEARCH CENTER, BY REGION, 2020–2028 ($MILLION)
TABLE 20.LIQUID BIOPSY MARKET REVENUE, BY REGION, 2020–2028 ($MILLION)
TABLE 21.NORTH AMERICA LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 22.NORTH AMERICA LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 23.NORTH AMERICA LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 24.NORTH AMERICA LIQUID BIOPSY MARKET, BY END USER, 2020–2028 ($MILLION)
TABLE 25.NORTH AMERICA LIQUID BIOPSY MARKET, BY COUNTRY, 2020–2028 ($MILLION)
TABLE 26.U.S. LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 27.U.S. LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 28.U.S. LIQUID BIOPSY MARKET, BY CANCER TYPE , 2020–2028 ($MILLION)
TABLE 29.U.S. LIQUID BIOPSY MARKET, BY END USER , 2020–2028 ($MILLION)
TABLE 30.CANADA LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 31.CANADA LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 32.CANADA LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 33.CANADA LIQUID BIOPSY MARKET, BY END USER, 2020–2028 ($MILLION)
TABLE 34.MEXICO LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 35.MEXICO LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 36.MEXICO. LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 37.MEXICO. LIQUID BIOPSY MARKET, BY END USER, 2020–2028 ($MILLION)
TABLE 38.EUROPE LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 39.EUROPE LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 40.EUROPE LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 41.EUROPE LIQUID BIOPSY MARKET, BY END USER, 2020–2028 ($MILLION)
TABLE 42.EUROPE LIQUID BIOPSY MARKET, BY COUNTRY, 2020–2028 ($MILLION)
TABLE 43.GERMANY LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 44.GERMANY LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 45.GERMANY LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 46.GERMANY LIQUID BIOPSY MARKET, BY END USER, 2020–2028 ($MILLION)
TABLE 47.FRANCE LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 48.FRANCE LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 49.FRANCE LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 50.FRANCE LIQUID BIOPSY MARKET, BY END USER, 2020–2028 ($MILLION)
TABLE 51.UK LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 52.UK LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 53.UK LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 54.UK LIQUID BIOPSY MARKET, BY END USER, 2020–2028 ($MILLION)
TABLE 55.ITALY LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 56.ITALY LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 57.ITALY LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 58.ITALY LIQUID BIOPSY MARKET, BY END USER, 2020–2028 ($MILLION)
TABLE 59.SPAIN LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 60.SPAIN LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 61.SPAIN LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 62.SPAIN LIQUID BIOPSY MARKET, BY END USER, 2020–2028 ($MILLION)
TABLE 63.REST OF EUROPE LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 64.REST OF EUROPE LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 65.REST OF EUROPE LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 66.REST OF EUROPE LIQUID BIOPSY MARKET, BY END USER, 2020–2028 ($MILLION)
TABLE 67.ASIA-PACIFIC LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 68.ASIA-PACIFIC LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 69.ASIA-PACIFIC LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 70.ASIA-PACIFIC LIQUID BIOPSY MARKET, BY END USER, 2020–2028 ($MILLION)
TABLE 71.ASIA-PACIFIC LIQUID BIOPSY MARKET, BY COUNTRY, 2020–2028 ($MILLION)
TABLE 72.JAPAN LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 73.JAPAN LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 74.JAPAN LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 75.JAPAN LIQUID BIOPSY MARKET, BY END USER, 2020–2028 ($MILLION)
TABLE 76.CHINA LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 77.CHINA LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 78.CHINA LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 79.CHINA LIQUID BIOPSY MARKET, BY END USER, 2020–2028 ($MILLION)
TABLE 80.AUSTRALIA LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 81.AUSTRALIA LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 82.AUSTRALIA LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 83.AUSTRALIA LIQUID BIOPSY MARKET, BY END USER, 2020–2028 ($MILLION)
TABLE 84.INDIA LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 85.INDIA LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 86.INDIA LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 87.INDIA LIQUID BIOPSY MARKET, BY END USER, 2020–2028 ($MILLION)
TABLE 88.SOUTH KOREA LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 89.SOUTH KOREA LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 90.SOUTH KOREA LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 91.SOUTH KOREA LIQUID BIOPSY MARKET, BY END USER, 2020–2028 ($MILLION)
TABLE 92.TAIWAN LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 93.TAIWAN LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 94.TAIWAN LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 95.TAIWAN LIQUID BIOPSY MARKET, BY END USER, 2020–2028 ($MILLION)
TABLE 96.REST OF ASIA-PACIFIC LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 97.REST OF ASIA-PACIFIC LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 98.REST OF ASIA-PACIFIC LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 99.REST OF ASIA-PACIFIC LIQUID BIOPSY MARKET, BY END USER, 2020–2028 ($MILLION)
TABLE 100.LAMEA LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 101.LAMEA LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 102.LAMEA LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 103.LAMEA LIQUID BIOPSY MARKET, BY END USER, 2020–2028 ($MILLION)
TABLE 104.LAMEA LIQUID BIOPSY MARKET, BY COUNTRY, 2020–2028 ($MILLION)
TABLE 105.BRAZIL LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 106.BRAZIL LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 107.BRAZIL LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 108.BRAZIL LIQUID BIOPSY MARKET, BY END USER, 2020–2028 ($MILLION)
TABLE 109.TURKEY LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 110.TURKEY LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 111.TURKEY LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 112.TURKEY LIQUID BIOPSY MARKET, BY END USER, 2020–2028 ($MILLION)
TABLE 113.SAUDI ARABIA LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 114.SAUDI ARABIA LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 115.SAUDI ARABIA LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 116.SAUDI ARABIA LIQUID BIOPSY MARKET, BY END USER, 2020–2028($MILLION)
TABLE 117.SOUTH AFRICA LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 118.SOUTH AFRICA LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 119.SOUTH AFRICA LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 120.SOUTH AFRICA LIQUID BIOPSY MARKET, BY END USER, 2020–2028 ($MILLION)
TABLE 121.REST OF LAMEA LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 122.REST OF LAMEA LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 123.REST OF LAMEA LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 124.REST OF LAMEA LIQUID BIOPSY MARKET, BY END USER, 2020–2028 ($MILLION)
TABLE 125.BIO-RAD: COMPANY SNAPSHOT
TABLE 126.MYRIAD: OERATING SEGMENT
TABLE 127.BIO-RAD: PRODUCT PORTFOLIO
TABLE 128.BIO-RAD: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 129.BIOCEPT: COMPANY SNAPSHOT
TABLE 130.BIOCEPT: PRODUCT PORTFOLIO
TABLE 131.BIOCEPT: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 132.GUARDANT: COMPANY SNAPSHOT
TABLE 133.GUARDANT: OPERATING SEGMENTS
TABLE 134.GUARDANT: PRODUCT PORTFOLIO
TABLE 135.BIOCEPT: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 136.ILLUMINA: COMPANY SNAPSHOT
TABLE 137.ILLUMINA: OPERATING SEGMENTS
TABLE 138.ILLUMINA: PRODUCT PORTFOLIO
TABLE 139.ROCHE: COMPANY SNAPSHOT
TABLE 140.ROCHE: OPERATING SEGMENTS
TABLE 141.ROCHE: PRODUCT PORTFOLIO
TABLE 142.ROCHE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 143.J&J: COMPANY SNAPSHOT
TABLE 144.J&J: OPERATING BUSINESS SEGMENTS
TABLE 145.J&J: PRODUCT PORTFOLIO
TABLE 146.LABCORP: COMPANY SNAPSHOT
TABLE 147.LABCORP: OPERATING SEGMENTS
TABLE 148.LABCORP: PRODUCT PORTFOLIO
TABLE 149.ROCHE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 150.MDXHEALTH: COMPANY SNAPSHOT
TABLE 151.MDXHEALTH: PRODUCT PORTFOLIO
TABLE 152.ROCHE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 153.QIAGEN: COMPANY SNAPSHOT
TABLE 154.QIAGEN: PRODUCT PORTFOLIO
TABLE 155.QIAGEN: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 156.THERMO: COMPANY SNAPSHOT
TABLE 157.THERMO: OPERATING SEGMENTS
TABLE 158.THERMO: PRODUCT PORTFOLIO
TABLE 159.THERMO: KEY STRATEGIC MOVES AND DEVELOPMENTS
Similar Reports
Medical implants are permanent devices such as pacemakers or temporary devices such as fracture plates which are removed once their function is completed. These implants are made up of bone, tissue, skin, ceramics, metals, plastics, and other natural materials...
- Publish Date: August 21, 2016
- $5370
Ostomy is a surgery wherein an artificial opening, known as stoma, is created from the colon in the human body to eliminate body wastes such as urine, mucus, and stools, which are collected in artificial bags called ostomy drainage bags. These plastic/rub...
- Publish Date: December 1, 2016
- $5370
Laparoscopy is a minimally invasive procedure used to examine organs inside the abdomen or pelvic cavities by inserting a laparoscope through a small incision in the abdomen. A laparoscope comprises a long, thin tube with high-intensity light, and high-re...
- Publish Date: April 24, 2017
- $5370
